RNXT
RenovoRx, Inc.
1W: +6.8%
1M: +22.0%
3M: +22.2%
YTD: +31.7%
1Y: +2.8%
3Y: -63.1%
$1.10
+0.02 (+1.85%)
After Hours: $1.12 (+0.02, +2.27%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$40.3M
52W Range0.701-1.45
Volume397,775
Avg Volume299,738
Beta1.33
Dividend—
Analyst Ratings
Company Info
CEOShaun R. Bagai
Employees10
SectorHealthcare
IndustryBiotechnology
IPO Date2021-08-26
Websiterenovorx.com
4546 El Camino Real
Mountain View, CA 94022
US
Mountain View, CA 94022
US
650 284 4433
About RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Latest News
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
RenovoRx announces $10 million private placement
CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates
Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Marton Laurence | P-Purchase | 9,720 | — | 2026-03-20 |
| Marton Laurence | P-Purchase | 4,860 | $1.93 | 2026-03-20 |
| Bagai Shaun | P-Purchase | 24,300 | — | 2026-03-20 |
| Bagai Shaun | P-Purchase | 12,150 | $1.93 | 2026-03-20 |
| VOLL MARK | P-Purchase | 97,200 | — | 2026-03-20 |